CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )
20 Jun 2019
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Using bioinformatics and genomics to treat AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019
Myeloma highlights from EHA 2019
Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain
Myeloma highlights from EHA 2019 ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )
15 Jun 2019
AlloHCT conditioning intensity in AML in complete remission with residual diseas...
Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, U...
AlloHCT conditioning intensity in AML in complete remission with residual disease ( Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA )
15 Jun 2019
D-VTd in induction prior to and consolidation after ASCT improves PFS and depth ...
Prof Philippe Moreau - Chu Nantes, Nantes, France
D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety ( Prof Philippe Moreau - Chu Nantes, Nantes, France )
14 Jun 2019
Intervention for AML patients with MRD can result in improved survival
Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lu...
Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )
14 Jun 2019
Novel adoptive cell therapies for acute lymphoblastic leukaemia
Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital an...
Novel adoptive cell therapies for acute lymphoblastic leukaemia ( Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany )
24 May 2019
Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse
Prof David Marks - University Hospital Bristol, Bristol, UK
Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse ( Prof David Marks - University Hospital Bristol, Bristol, UK )
24 May 2019
Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromo...
Prof Hervé Dombret, University Paris Diderot, Paris, France
Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Prof Hervé Dombret, University Paris Diderot, Paris, France )
24 May 2019
Advanced HCC: New systemic treatment options
Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt
Advanced HCC: New systemic treatment options ( Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt )
8 May 2019
The WIN symposium 2019
Prof Razelle Kurzrock - University of California San Diego, San Diego, USA
The WIN symposium 2019 ( Prof Razelle Kurzrock - University of California San Diego, San Diego, USA )
25 Apr 2019